Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

NCT ID: NCT02128945

Last Updated: 2016-09-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-04-30
• Study Completion Date: 2016-05-31

Brief Summary

The application of positron emission tomography with lymphoproliferative diseases today provides diagnostic and therapeutic information of major importance , especially in terms of speed and quality of response to treatment. The radiopharmaceutical used in clinical practice for this exam is fluorodeoxyglucose 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose ([18F]-FDG) . However , the uptake of this tracer is not elective in lymphoid tissues , with a lack of specificity. In addition , the avidity of this tracer is unequal according to the histological subtype (lack of sensitivity).

To try to improve the results of this clinical exploration of lymphoid malignancies, the investigators developed a new radiopharmaceutical ( [18F] - fludarabine ). The idea of transforming the fludarabine radiopharmaceutical is based on the existence of a fluorine atom in the molecule and the pharmacokinetic characteristics of this drug. The [18F]-Fludarabine is a new radiopharmaceutical reproducing the same dosage formulation of fludarabine , a drug used for the treatment of certain types of lymphoproliferative diseases, especially those where the tumor cells have a low proliferation kinetics . This drug is used in therapy in particular pharmacokinetic effect for a high affinity for the lymphoid tissue . Preclinical results on normal and lymphoma xenograft -bearing mice showed a specificity restricted to lymphoid tissue fixation with [18F]-Fludarabine compared with [18F]-FDG .

Based on these encouraging results , the investigators propose in this work to explore the Dosimetry and Biodistribution of [18F] - Fludarabine in human lymphoproliferative diseases : 1)A first group of patients with non-Hodgkin's large cell lymphomas in which it already has a wealth of experience in exploration [18F]-FDG, and 2) a second group of patients with chronic lymphocytic leukemia, where the results of the exploration [18F]-FDG are considered disappointing and did not, for this reason, experienced clinical development.

Conditions

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

FLUDATEP

\[18F\] - Fludarabine PET/CT

Group Type: EXPERIMENTAL

[18F] - Fludarabine PET/CT

Intervention Type: OTHER

\[18F\] - Fludarabine PET/CT before treatment

Interventions

[18F] - Fludarabine PET/CT

\[18F\] - Fludarabine PET/CT before treatment

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adult over 18
• Signed written informed consent
• Untreated stage B or C chronic lymphocytic leukemia
• Untreated diffuse large B-cell lymphoma
• Eligible for PET-CT
• The subject must be covered by a social security system

Exclusion Criteria

• Age under 18
• Patients concurrently included in an investigational trial
• Weight over 120 kg
• pregnant women
• active infectious disease
• immune hemolytic anemia
• patients with creatinine clearance < 30 ml/mn
• corticosteroid therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

UNKNOWN

Sponsor Role: collaborator

University Hospital, Caen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sylvain P CHANTEPIE, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Caen

Locations

University Hospital

Caen, , France

Countries

France

Other Identifiers

13-090

Identifier Type: -

Identifier Source: secondary_id

2013-002796-18

Identifier Type: -

Identifier Source: org_study_id